ICON6: An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Sponsor

Medical Research Council (Other)

Overall Status

Unknown status

CT.gov ID

NCT00532194

Collaborator

Cancer Research UK (Other), National Health and Medical Research Council, Australia (Other), Australia New Zealand Gynaecological Oncology Group (Other), NCIC Clinical Trials Group (Other), Grupo Español de Investigación en Cáncer de Ovario (Other), AstraZeneca (Industry)

486

Enrollment

Location

Arms

113.1

Duration (Months)

4.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Cancer	Drug: cediranib	Phase 3

Detailed Description

ICON6 is a randomised three-arm, two stage, double-blind, placebo-controlled multicentre Gynaecologic Cancer InterGroup (GCIG) phase III trial.

All patients will receive 6 cycles of platinum-based chemotherapy. Trial drug will be administered for up to 18 months from randomisation or until progression, whichever is sooner. Patients who have not progressed at 18 months from randomisation can continue Trial Drug until progression, if in the opinion of the clinician and the patient there is continuing clinical benefit.

Patients in Arm A (the reference arm) will receive a platinum-based chemotherapy regimen plus a daily oral placebo tablet for the duration of the chemotherapy and up to 18 months from randomisation or until progression.

Patients in Arm B (concurrent cediranib arm) will also receive a platinum-based chemotherapy regimen plus daily oral cediranib during chemotherapy only, and then an oral daily placebo tablet up to 18 months from randomisation or until progression.

Patients in Arm C (concurrent and maintenance cediranib arm) will also receive a platinum-based chemotherapy regimen plus oral cediranib daily during chemotherapy and then continued up to 18 months from randomisation or until progression.

Study Design

Study Type:

Interventional

Actual Enrollment :

486 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Study Start Date :

Jul 1, 2007

Actual Primary Completion Date :

Apr 1, 2013

Anticipated Study Completion Date :

Dec 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: A (reference) Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
Active Comparator: B (concurrent cediranib) Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.	Drug: cediranib Once-daily oral tablet starting dose 20mg Other Names: AZD2171 Recentin
Active Comparator: C (concurrent and maintenance cediranib) Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.	Drug: cediranib Once-daily oral tablet starting dose 20mg Other Names: AZD2171 Recentin

Arm

Intervention/Treatment

Placebo Comparator: A (reference)

Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.

Active Comparator: B (concurrent cediranib)

Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.

Drug: cediranib

Once-daily oral tablet starting dose 20mg

Other Names:

AZD2171

Recentin

Active Comparator: C (concurrent and maintenance cediranib)

Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.

Drug: cediranib

Once-daily oral tablet starting dose 20mg

Other Names:

AZD2171

Recentin

Outcome Measures

Primary Outcome Measures

Progression-free survival [Apr 2013]

Secondary Outcome Measures

Overall survival [Q2 2016]
Toxicity [Q2 2015]
Quality of Life [Q2 2015]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Females aged >= 18 years with previous histologically proven diagnosis of

Epithelial ovarian carcinoma
Fallopian tube carcinoma
Primary serous peritoneal carcinoma requiring treatment with further platinum-based chemotherapy > 6 months after their last cycle of first-line chemotherapy and 6 weeks after maintenance that is not chemotherapy based.

Signed informed consent and ability to comply with the protocol
Ability to commence treatment within approximately 2 weeks of randomisation
CT or MRI proven relapsed disease (measurable or non-measurable)
ECOG performance status 0-1
Life expectancy more than 12 weeks
If there is a past history of a solid tumour (other than ovarian cancer), this must have been treated curatively more than five years ago with no evidence of recurrence, with the exception of patients who have synchronous endometrial cancer (stage I G1, G2) with their ovarian cancer
If prior anthracycline or chest radiotherapy, Left Ventricular Ejection Fraction (LVEF) > institutional lower limit of normal.
Adequate bone marrow function

Absolute Neutrophil Count (ANC) >= 1.5 x 109/l
Platelets (Plt) >= 100 x 109/l
Haemoglobin (Hb) >= 9g/dl (can be post transfusion)

Adequate liver function (within 14 days before randomisation)

Serum bilirubin (BR) ≤ 1.5 x ULN
Serum transaminases ≤ 2.5 x ULN

Adequate renal function

Serum creatinine ≤ 1.5 ULN or calculated creatinine clearance > 50 ml/min
Urine dipstick for proteinuria <2+. If urine dipstick is >= 2+ on two occasions more than one week apart then a 24 hour urine must demonstrate <=1g of protein in 24 hours or protein/creatinine ratio <1.5

Exclusion Criteria:

Non-epithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum
Poorly controlled hypertension (persistently elevated > 150/100mmHg, either systolic or diastolic or both, despite anti-hypertensive medication)
History of inflammatory bowel disease (Crohn's disease or Ulcerative Colitis)
Malignancies other than ovarian cancer within 5 years prior to randomisation, except for synchronous endometrial cancer (Stage I G1,G2) with ovarian cancer,adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer. Patients who have a past history of a solid tumour, treated curatively, more than five years prior to randomisation, with no evidence of recurrence, are still eligible to enter ICON6.
Previous radiotherapy within 21 days prior to anticipated start of treatment
Treatment with any other investigational agent within 6 weeks prior to entering this trial. Patients are still eligible for entry into ICON6 if they have received previous treatment for ovarian cancer with either bevacizumab, erlotinib, or a Cox-2 inhibitor as long as more than 6 weeks have elapsed since the last treatment.
Arterial thrombotic event (including transient ischaemic attack [TIA], cerebrovascular accident [CVA) and peripheral arterial embolus) within the previous 12 months.
GI impairment that could affect ability to take, or adsorption of, oral medicines including sub acute or complete bowel obstruction
Known hypersensitivity to cediranib or other VEGF inhibitors
Major surgery within 2 weeks before anticipated start of treatment
Significant haemorrhage of > 30ml in a single episode within 3 months or any haemoptysis
Evidence of severe or uncontrolled cardiac disease

Myocardial infarct [MI] or unstable angina within 12 months
New York Health Association (NYHA) ≥ grade 2 congestive heart failure (CHF)
Cardiac ventricular arrhythmias requiring medication.
History of 2nd or 3rd degree atrioventricular conduction defects.

Prolonged QTc (corrected) interval of > 470msec on ECG, or a family history of long QT syndrome.
Persisting ≥ Grade 2 CTC toxicity (except alopecia and neuropathy) from previous anti-cancer treatment. If peripheral sensory or motor neuropathy ≥ grade 2 then paclitaxel can be omitted from the chemotherapy at the discretion of the treating physician
History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory in the case of suspected brain metastases. Spinal MRI is mandatory in the case of suspected spinal cord compression. Patients with unstable, untreated brain or meningeal metastases are not eligible.
Inability to attend or comply with treatment or follow-up scheduling
Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
Fertile women of childbearing potential not willing to use adequate contraception for the duration of trial treatment and at least 6 months after.
Any other severe uncontrolled medical condition or disease
Concomitant use of potent inhibitors of CYP3A4 and 2C8 which cannot be stopped without a 2 week washout period before starting Trial Drug.